Shin-Ichi Murata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shin-Ichi Murata has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
Fumiyoshi Kojima
Department of Human Pathology, Wakayama Medical University, Wakayama, Japan
17 shared publicationsIbu Matsuzaki
Department of Human Pathology, Wakayama Medical University, Wakayama, Japan
17 shared publicationsYuichi Takahashi
Department of Human Pathology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan
11 shared publicationsYurina Mikasa
Department of Human Pathology, Wakayama Medical University, Wakayama, Japan
9 shared publicationsKenji Warigaya
Division of Diagnostic Pathology Shin‐kuki General Hospital Kuki Saitama Japan
8 shared publications- Ibu Matsuzaki
Department of Human Pathology, Wakayama Medical University, Wakayama, Japan
7 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Wolters Kluwer Health in Cornea
A Case of Leukemic Phase of Mantle Cell Lymphoma Diagnosed With Scarring Conjunctivitis and Bilateral Upper Palpebral Conjunctival Tumor
Purpose: Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin's lymphoma. Ocular adnexal involvement is rare as the initial symptom, and conjunctival involvement is particularly rare. Methods: An 84-year-old man was referred to our hospital with chronic conjunctivitis of the bulbar and tarsal conjunctiva with bilateral symblepharon, as well as a reddish-brown, cobblestone-like tumor. Results: Suspecting malignancy, a tumor biopsy and systemic examination revealed the neoplastic lesion to be MCL. Leukocytosis and abnormal cells in peripheral blood (53%) were observed, and diffuse tumor cell infiltration was observed in the bone marrow. Both the bone marrow and tumor cells were positive for CD5, CD20, and cyclin D1, while the bone marrow tissue was negative for SOX11, confirming leukemic conversion (leukemic phase of mantle cell lymphoma). PET/CT revealed accumulation in systemic lymph nodes and extranodal organs, leading to a diagnosis of Ann Arbor stage IV disease. TP53 deletion was not detected. Following treatment with acalabrutinib in combination with bendamustine and rituximab, as reported in 2025, the conjunctivitis and eyelid tumor resolved, with no recurrence observed during follow-up. Conclusion: We report a case of leukemia-type MCL diagnosed with bilateral chronic cicatricial conjunctivitis and elevated lesions on the upper eyelid conjunctiva as initial findings. When encountering such findings, early pathological diagnosis and thorough systemic examination are important, with systemic malignant lymphoma in mind.
- 21 September 2026
- Published by Wolters Kluwer Health in Cornea
Open AccessA Case of Leukemic Phase of Mantle Cell Lymphoma Diagnosed With Scarring Conjunctivitis and Bilateral Upper Palpebral Conjunctival Tumor
Purpose: Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin's lymphoma. Ocular adnexal involvement is rare as the initial symptom, and conjunctival involvement is particularly rare. Methods: An 84-year-old man was referred to our hospital with chronic conjunctivitis of the bulbar and tarsal conjunctiva with bilateral symblepharon, as well as a reddish-brown, cobblestone-like tumor. Results: Suspecting malignancy, a tumor biopsy and systemic examination revealed the neoplastic lesion to be MCL. Leukocytosis and abnormal cells in peripheral blood (53%) were observed, and diffuse tumor cell infiltration was observed in the bone marrow. Both the bone marrow and tumor cells were positive for CD5, CD20, and cyclin D1, while the bone marrow tissue was negative for SOX11, confirming leukemic conversion (leukemic phase of mantle cell lymphoma). PET/CT revealed accumulation in systemic lymph nodes and extranodal organs, leading to a diagnosis of Ann Arbor stage IV disease. TP53 deletion was not detected. Following treatment with acalabrutinib in combination with bendamustine and rituximab, as reported in 2025, the conjunctivitis and eyelid tumor resolved, with no recurrence observed during follow-up. Conclusion: We report a case of leukemia-type MCL diagnosed with bilateral chronic cicatricial conjunctivitis and elevated lesions on the upper eyelid conjunctiva as initial findings. When encountering such findings, early pathological diagnosis and thorough systemic examination are important, with systemic malignant lymphoma in mind.
- 11 May 2026
- Published by Elsevier in Pathology - Research and Practice
- Vol. 284, 156517
Precursor flat urothelial lesions: Molecular landscape, pathogenesis, and biological insights
- 11 May 2026
- Published by Elsevier in Pathology - Research and Practice
- Vol. 284, 156517
Precursor flat urothelial lesions: Molecular landscape, pathogenesis, and biological insights
- 28 March 2026
- Published by Springer Nature in Virchows Archiv
Complex aberrant expression of planar nuclear polarity factors in intraductal papillary mucinous neoplasm of the pancreas
Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are classified into low grade (LG), high grade (HG), and invasive carcinoma-associated (IC) groups, each requiring different clinical therapeutic strategies. Loss of planar nuclear polarity (PNP) in IPMNs is a key factor in tumor progression. We studied 29 IPMN cases (8 LG, 10 HG, and 11 IC) using targeted next-generation sequencing and immunohistochemistry to elucidate the complex molecular dynamics of PNP factors in tumor progression. We analyzed the mRNA expression of 61 PNP-related factors, including those associated with the cell membrane, epithelial-mesenchymal transition (EMT), the Hippo pathway, cytoskeletal network, and nuclear envelope, in the IPMN cases. The Kruskal-Wallis test identified 15 PNP factors (ITGB1, CLDN4, CLDN7, ANO1, TWIST1, SRSF1, LATS2, TOP2A, MAPK1, TGFBR1, PCNT, FSCN1, RHOA, CDC42, and SYNE3) with significantly higher mRNA expression in IC compared with LG and HG. Multinomial logistic regression identified three PNP factors (CLDN7, FSCN1, and TOP2A) with significantly higher mRNA expression and stronger or more frequent immunohistochemical positivity in both LG versus IC and LG versus HG comparisons. Overall, our study indicates that the molecular mechanisms underlying disturbed PNP in IPMNs are not mediated by a single pathway but involve multiple interconnected pathways. Our findings may contribute to elucidation of the molecular mechanisms regulating PNP in IPMNs, enhancing our understanding of tumor progression and contributing to more accurate pathological diagnosis.
- 28 March 2026
- Published by Springer Nature in Virchows Archiv
Complex aberrant expression of planar nuclear polarity factors in intraductal papillary mucinous neoplasm of the pancreas
Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are classified into low grade (LG), high grade (HG), and invasive carcinoma-associated (IC) groups, each requiring different clinical therapeutic strategies. Loss of planar nuclear polarity (PNP) in IPMNs is a key factor in tumor progression. We studied 29 IPMN cases (8 LG, 10 HG, and 11 IC) using targeted next-generation sequencing and immunohistochemistry to elucidate the complex molecular dynamics of PNP factors in tumor progression. We analyzed the mRNA expression of 61 PNP-related factors, including those associated with the cell membrane, epithelial-mesenchymal transition (EMT), the Hippo pathway, cytoskeletal network, and nuclear envelope, in the IPMN cases. The Kruskal-Wallis test identified 15 PNP factors (ITGB1, CLDN4, CLDN7, ANO1, TWIST1, SRSF1, LATS2, TOP2A, MAPK1, TGFBR1, PCNT, FSCN1, RHOA, CDC42, and SYNE3) with significantly higher mRNA expression in IC compared with LG and HG. Multinomial logistic regression identified three PNP factors (CLDN7, FSCN1, and TOP2A) with significantly higher mRNA expression and stronger or more frequent immunohistochemical positivity in both LG versus IC and LG versus HG comparisons. Overall, our study indicates that the molecular mechanisms underlying disturbed PNP in IPMNs are not mediated by a single pathway but involve multiple interconnected pathways. Our findings may contribute to elucidation of the molecular mechanisms regulating PNP in IPMNs, enhancing our understanding of tumor progression and contributing to more accurate pathological diagnosis.
- Retracted
- 11 December 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 57, 102595
Value of single-photon emission computed tomography for diagnosing transthyretin amyloid cardiomyopathy: Correlation with endomyocardial biopsy
- 11 December 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 57, 102595
RetractedValue of single-photon emission computed tomography for diagnosing transthyretin amyloid cardiomyopathy: Correlation with endomyocardial biopsy
- Open Access
- 14 October 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (20) , 2285
Flower-Shaped Plasma Cells in Multiple Myeloma with Morphological Heterogeneity
Background: Flower-shaped nuclei in plasma cells are rare in multiple myeloma. Case presentation: We report on an 88-year-old male who presented with a mass lesion in the clavicular region. A biopsy of the mass revealed an increase in mature plasma cells with round nuclei. In contrast, a bone marrow examination showed increased plasma cells with flower-shaped nuclei. The patient tested negative for human T-lymphotropic virus type-1 and was diagnosed with multiple myeloma. Conclusions: While multiple myeloma is known for intra-tumor heterogeneity, reports of morphological heterogeneity based on the site of tumor sampling are limited. In this case, the presence of plasma cells with flower-shaped nuclei enabled the identification of site-dependent morphological tumor heterogeneity.
- 14 October 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (20) , 2285
Open AccessFlower-Shaped Plasma Cells in Multiple Myeloma with Morphological Heterogeneity
Background: Flower-shaped nuclei in plasma cells are rare in multiple myeloma. Case presentation: We report on an 88-year-old male who presented with a mass lesion in the clavicular region. A biopsy of the mass revealed an increase in mature plasma cells with round nuclei. In contrast, a bone marrow examination showed increased plasma cells with flower-shaped nuclei. The patient tested negative for human T-lymphotropic virus type-1 and was diagnosed with multiple myeloma. Conclusions: While multiple myeloma is known for intra-tumor heterogeneity, reports of morphological heterogeneity based on the site of tumor sampling are limited. In this case, the presence of plasma cells with flower-shaped nuclei enabled the identification of site-dependent morphological tumor heterogeneity.
- 21 August 2024
- Published by Springer Nature in Virchows Archiv
- Vol. 486 (4) , 729-737
Comparative analysis of non-coding and coding DNA mutations in flat urothelial lesions: biological implications and insights
Recent research in urothelial carcinoma (UC) has focused on coding mutations, leaving the significance of non-coding mutations unexplored. This study aims to evaluate non-coding DNA mutation frequencies compared to coding regions in normal urothelium and flat lesions, exploring their implications for tumor biology. Using targeted next-generation sequencing with UC-related gene panel, we analyzed non-coding and coding DNA mutation frequencies across 119 samples of flat urothelium encompassing various lesion types. Mutation patterns were examined based on the presence of associated flat or papillary tumors, and we investigated the correlation between mutation rates in target genes and genetic mutations within genomic regions. Intronic mutations (IMs) displayed variability across lesions, with normal urothelium (NU) exhibiting the highest frequency (43%) and urothelial carcinoma in situ (CIS) the lowest (9%). We observed similar sets of frequently mutated genes in both intronic and exonic regions, distinct from promoter region mutations. Although IMs paralleled exonic mutations in NU, reactive atypia, and atypia of unknown significance (AUS), they were less prevalent in dysplasia (DYS) and CIS. In contrast to CIS-associated AUS and DYS lesions, AUS-DYS lesions associated with papillary tumors exclusively exhibited recurrent intronic mutations involving FGFR3 and ERCC2, aligning with mutation patterns seen in exonic regions. ERCC2 intronic mutations correlated with the mutation rates of the gene panel. Our findings suggest that intronic mutations significantly contribute to tumor heterogeneity in urothelial lesions and may potentially be linked to genomic instability, warranting further investigation.
- 21 August 2024
- Published by Springer Nature in Virchows Archiv
- Vol. 486 (4) , 729-737
Comparative analysis of non-coding and coding DNA mutations in flat urothelial lesions: biological implications and insights
Recent research in urothelial carcinoma (UC) has focused on coding mutations, leaving the significance of non-coding mutations unexplored. This study aims to evaluate non-coding DNA mutation frequencies compared to coding regions in normal urothelium and flat lesions, exploring their implications for tumor biology. Using targeted next-generation sequencing with UC-related gene panel, we analyzed non-coding and coding DNA mutation frequencies across 119 samples of flat urothelium encompassing various lesion types. Mutation patterns were examined based on the presence of associated flat or papillary tumors, and we investigated the correlation between mutation rates in target genes and genetic mutations within genomic regions. Intronic mutations (IMs) displayed variability across lesions, with normal urothelium (NU) exhibiting the highest frequency (43%) and urothelial carcinoma in situ (CIS) the lowest (9%). We observed similar sets of frequently mutated genes in both intronic and exonic regions, distinct from promoter region mutations. Although IMs paralleled exonic mutations in NU, reactive atypia, and atypia of unknown significance (AUS), they were less prevalent in dysplasia (DYS) and CIS. In contrast to CIS-associated AUS and DYS lesions, AUS-DYS lesions associated with papillary tumors exclusively exhibited recurrent intronic mutations involving FGFR3 and ERCC2, aligning with mutation patterns seen in exonic regions. ERCC2 intronic mutations correlated with the mutation rates of the gene panel. Our findings suggest that intronic mutations significantly contribute to tumor heterogeneity in urothelial lesions and may potentially be linked to genomic instability, warranting further investigation.
- 18 June 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 178, 108774
Small sized centroblasts as poor prognostic factor in follicular lymphoma - Based on artificial intelligence analysis
- 18 June 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 178, 108774
Small sized centroblasts as poor prognostic factor in follicular lymphoma - Based on artificial intelligence analysis
- 2 January 2024
- Published by Springer Nature in Endocrine Pathology
- Vol. 35 (1) , 40-50
Artificial Intelligence Detected the Relationship Between Nuclear Morphological Features and Molecular Abnormalities of Papillary Thyroid Carcinoma
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma and has characteristic nuclear features. Genetic abnormalities of PTC affect recent molecular target therapeutic strategy towards RET-altered cases, and they affect clinical prognosis and progression. However, there has been insufficient objective analysis of the correlation between genetic abnormalities and nuclear features. Using our newly developed methods, we studied the correlation between nuclear morphology and molecular abnormalities of PTC with the aim of predicting genetic abnormalities of PTC. We studied 72 cases of PTC and performed genetic analysis to detect BRAF p.V600E mutation and RET fusions. Nuclear features of PTC, such as nuclear grooves, pseudo-nuclear inclusions, and glassy nuclei, were also automatically detected by deep learning models. After analyzing the correlation between genetic abnormalities and nuclear features of PTC, logistic regression models could be used to predict gene abnormalities. Nuclear features were accurately detected with over 0.90 of AUCs in every class. The ratio of glassy nuclei to nuclear groove and the ratio of pseudo-nuclear inclusion to glassy nuclei were significantly higher in cases that were positive for RET fusions (p = 0.027, p = 0.043, respectively) than in cases that were negative for RET fusions. RET fusions were significantly predicted by glassy nuclei/nuclear grooves, pseudo-nuclear inclusions/glassy nuclei, and age (p = 0.023). Our deep learning models could accurately detect nuclear features. Genetic abnormalities had a correlation with nuclear features of PTC. Furthermore, our artificial intelligence model could significantly predict RET fusions of classic PTC.
- 2 January 2024
- Published by Springer Nature in Endocrine Pathology
- Vol. 35 (1) , 40-50
Artificial Intelligence Detected the Relationship Between Nuclear Morphological Features and Molecular Abnormalities of Papillary Thyroid Carcinoma
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma and has characteristic nuclear features. Genetic abnormalities of PTC affect recent molecular target therapeutic strategy towards RET-altered cases, and they affect clinical prognosis and progression. However, there has been insufficient objective analysis of the correlation between genetic abnormalities and nuclear features. Using our newly developed methods, we studied the correlation between nuclear morphology and molecular abnormalities of PTC with the aim of predicting genetic abnormalities of PTC. We studied 72 cases of PTC and performed genetic analysis to detect BRAF p.V600E mutation and RET fusions. Nuclear features of PTC, such as nuclear grooves, pseudo-nuclear inclusions, and glassy nuclei, were also automatically detected by deep learning models. After analyzing the correlation between genetic abnormalities and nuclear features of PTC, logistic regression models could be used to predict gene abnormalities. Nuclear features were accurately detected with over 0.90 of AUCs in every class. The ratio of glassy nuclei to nuclear groove and the ratio of pseudo-nuclear inclusion to glassy nuclei were significantly higher in cases that were positive for RET fusions (p = 0.027, p = 0.043, respectively) than in cases that were negative for RET fusions. RET fusions were significantly predicted by glassy nuclei/nuclear grooves, pseudo-nuclear inclusions/glassy nuclei, and age (p = 0.023). Our deep learning models could accurately detect nuclear features. Genetic abnormalities had a correlation with nuclear features of PTC. Furthermore, our artificial intelligence model could significantly predict RET fusions of classic PTC.
- Open Access
- 25 November 2023
- Published by MDPI AG in Hematology Reports
- Vol. 15 (4) , 662-669
Angioimmunoblastic T-Cell Lymphoma after Treatment of Classic Hodgkin Lymphoma: A Case Report
We report a case of a 24-year-old man who developed angioimmunoblastic T-cell lymphoma (AITL) after treatment for refractory lymphocyte-rich classic Hodgkin lymphoma (LR-CHL). This patient was treated with the BV+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) protocol for LR-CHL but progressed before completing chemotherapy. The pathological imaging showed the typical findings of LR-CHL at the first onset and first progression. Rescue chemotherapy and high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (AHSCT) were performed for refractory LR-CHL, and complete remission was achieved. However, the recurrence was suspected 6 months after AHSCT. The pathological findings of the lymph node biopsy at this time were different from those of the previous two lymph node biopsies, demonstrating findings of AITL. The finding of the immunohistochemical staining and polymerase chain reaction results supported the diagnosis. Although it has been reported that the risk for the development of non-Hodgkin lymphoma after treatment for Hodgkin lymphoma is increased, most are B-cell lymphomas, and few cases of AITL have been reported. AITL is a type of peripheral T-cell lymphoma that generally occurs in middle-aged and elderly people and that rarely occurs in young people. Here, we were able to make an accurate diagnosis by performing re-examination even when recurrence of LR-CHL was suspected. As there are no detailed case reports of AITL developing into secondary non-Hodgkin lymphoma, here we report on an identified case.
- 25 November 2023
- Published by MDPI AG in Hematology Reports
- Vol. 15 (4) , 662-669
Open AccessAngioimmunoblastic T-Cell Lymphoma after Treatment of Classic Hodgkin Lymphoma: A Case Report
We report a case of a 24-year-old man who developed angioimmunoblastic T-cell lymphoma (AITL) after treatment for refractory lymphocyte-rich classic Hodgkin lymphoma (LR-CHL). This patient was treated with the BV+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) protocol for LR-CHL but progressed before completing chemotherapy. The pathological imaging showed the typical findings of LR-CHL at the first onset and first progression. Rescue chemotherapy and high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (AHSCT) were performed for refractory LR-CHL, and complete remission was achieved. However, the recurrence was suspected 6 months after AHSCT. The pathological findings of the lymph node biopsy at this time were different from those of the previous two lymph node biopsies, demonstrating findings of AITL. The finding of the immunohistochemical staining and polymerase chain reaction results supported the diagnosis. Although it has been reported that the risk for the development of non-Hodgkin lymphoma after treatment for Hodgkin lymphoma is increased, most are B-cell lymphomas, and few cases of AITL have been reported. AITL is a type of peripheral T-cell lymphoma that generally occurs in middle-aged and elderly people and that rarely occurs in young people. Here, we were able to make an accurate diagnosis by performing re-examination even when recurrence of LR-CHL was suspected. As there are no detailed case reports of AITL developing into secondary non-Hodgkin lymphoma, here we report on an identified case.
- 21 November 2023
- Published by Wiley in Histopathology
- Vol. 84 (3) , 539-549
Clinicopathological and molecular features of renal cell carcinomas with haemangioblastoma‐like features distinct from clear cell renal cell carcinoma
Aims: Haemangioblastomas arise in the central nervous system. Rarely, haemangioblastomas may develop in extra‐neural sites, such as the kidneys. A few reported cases of renal cell carcinomas (RCCs) with haemangioblastoma‐like features have exhibited both clear cell renal cell carcinoma (CCRCC)‐ and haemangioblastoma‐like components. The clinicopathological and molecular characteristics of RCCs with haemangioblastoma‐like features were analysed, focusing on VHL alterations, in comparison with CCRCCs partially resembling haemangioblastoma.Methods and Results: Four RCCs with haemangioblastoma‐like features and five CCRCCs partially resembling haemangioblastoma were included. The RCCs with haemangioblastoma‐like features were indolent and lacked adverse prognostic factors. All RCCs with haemangioblastoma‐like features had a well‐circumscribed appearance and a thick fibromuscular capsule, with fibromuscular bundles extending into the tumour to varying degrees in the three tumours. Each RCC with haemangioblastoma‐like features exhibited CCRCC‐like areas with indistinct tubular structures and foci of haemangioblastoma‐like areas, in which vessels and short spindle cells overwhelmed tumour cells. Whereas haemangioblastoma‐like areas in the CCRCCs partially resembling haemangioblastoma exhibited sparse vessels and spindle cells and distinct clear cells. The RCCs with haemangioblastoma‐like features exhibited a unique immunohistochemical profile, with positive staining for inhibin‐α, S100, carbonic‐anhydrase‐9, keratin7, and high molecular weight keratin and negative staining for (alpha‐methylacyl‐CoA racemase) AMACR. RCC with haemangioblastoma‐like features did not display any VHL alterations, including VHL mutation, 3p LOH, and methylation of the VHL promoter region, and the two tumours harboured a likely oncogenic missense variant of MTOR (c.7280T>G).Conclusion: The histopathological, immunohistochemical, and molecular findings suggest that RCC with haemangioblastoma‐like features is a distinct entity from CCRCC.
- 21 November 2023
- Published by Wiley in Histopathology
- Vol. 84 (3) , 539-549
Clinicopathological and molecular features of renal cell carcinomas with haemangioblastoma‐like features distinct from clear cell renal cell carcinoma
Aims: Haemangioblastomas arise in the central nervous system. Rarely, haemangioblastomas may develop in extra‐neural sites, such as the kidneys. A few reported cases of renal cell carcinomas (RCCs) with haemangioblastoma‐like features have exhibited both clear cell renal cell carcinoma (CCRCC)‐ and haemangioblastoma‐like components. The clinicopathological and molecular characteristics of RCCs with haemangioblastoma‐like features were analysed, focusing on VHL alterations, in comparison with CCRCCs partially resembling haemangioblastoma.Methods and Results: Four RCCs with haemangioblastoma‐like features and five CCRCCs partially resembling haemangioblastoma were included. The RCCs with haemangioblastoma‐like features were indolent and lacked adverse prognostic factors. All RCCs with haemangioblastoma‐like features had a well‐circumscribed appearance and a thick fibromuscular capsule, with fibromuscular bundles extending into the tumour to varying degrees in the three tumours. Each RCC with haemangioblastoma‐like features exhibited CCRCC‐like areas with indistinct tubular structures and foci of haemangioblastoma‐like areas, in which vessels and short spindle cells overwhelmed tumour cells. Whereas haemangioblastoma‐like areas in the CCRCCs partially resembling haemangioblastoma exhibited sparse vessels and spindle cells and distinct clear cells. The RCCs with haemangioblastoma‐like features exhibited a unique immunohistochemical profile, with positive staining for inhibin‐α, S100, carbonic‐anhydrase‐9, keratin7, and high molecular weight keratin and negative staining for (alpha‐methylacyl‐CoA racemase) AMACR. RCC with haemangioblastoma‐like features did not display any VHL alterations, including VHL mutation, 3p LOH, and methylation of the VHL promoter region, and the two tumours harboured a likely oncogenic missense variant of MTOR (c.7280T>G).Conclusion: The histopathological, immunohistochemical, and molecular findings suggest that RCC with haemangioblastoma‐like features is a distinct entity from CCRCC.